Serotoninergic neuroenteric modulators

Lancet

Volumn 358, Issue 9298, 2001, Pages 2061-2068

  Talley, Nicholas J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4,5,6,7 TETRAHYDRO 5 (1 INDOLYLCARBONYL)BENZIMIDAZOLE; ALOSETRON; CILANSETRON; CIMETROPIUM; CISAPRIDE; CLONIDINE; DEXLOXIGLUMIDE; DIPHENOXYLATE; FEDOTOZINE; GRANISETRON; LIDAMIDINE; LOPERAMIDE; MEBEVERINE; MISOPROSTOL; ONDANSETRON; OTILONIUM BROMIDE; PIBOSEROD; PRUCALOPRIDE; RENZAPRIDE; SCOPOLAMINE; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN 4 AGONIST; SEROTONIN 4 ANTAGONIST; SEROTONIN 4 RECEPTOR; SOMATOSTATIN DERIVATIVE; TEGASEROD; TRIMEBUTINE; ZELNOM;

ABDOMINAL PAIN; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; FLATULENCE; HUMAN; INTESTINE INNERVATION; IRRITABLE COLON; ISCHEMIC COLITIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0035894575     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)07103-3     Document Type: Review

References (97)

1. Epidemiology of colonic symptoms and the irritable bowel syndrome
2. Irritable bowel syndrome: A technical review for guidelines development
3. Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria
4. Medical costs in community subjects with irritable bowel syndrome
5. The impact of functional gastrointestinal disorders (FGIDS) on quality of life
6. The impact of irritable bowel syndrome on health-related quality of life
7. Irritable bowel syndrome symptom patterns: Frequency, duration, and severity
8. The short-term natural history of irritable bowel syndrome: A time-series analysis
9. Evidence of a genetic contribution to functional bowel disorder
10. Risk factors for irritable bowel syndrome: Role of analgesics and food sensitivities
11. Psychometric scores and persistence of irritable bowel after infectious diarrhoea
12. The role of psychological and biological factors in postinfective gut dysfunction
13. Terminal ileal mucosal mast cells in irritable bowel syndrome
14. Mast cell infiltration and degranulation in colonic mucosa in the irritable bowel syndrome
15. Increased rectal mucosal entero-endocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome
16. Symptoms of irritable bowel syndrome in ulcerative colitis in remission
17. IL-10 and TGFβ genotypes in irritable bowel syndrome: Evidence to support an inflammatory component?
18. Histopathological findings in the jejunum of patients with severe irritable bowel syndrome
19. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome
20. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and non-painful rectal distension
21. The irritable bowel syndrome: Long term prognosis and the patient-physician interaction
22. Serotonin: A mediator of the brain-gut connection
23. Treatment of irritable bowel syndrome: A review of randomised controlled trials
24. Roles played by 5-hydroxytryptamine in the physiology of the bowel
25. 3 receptor antagonists in the treatment of irritable bowel syndrome
26. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: A pilot study
27. 2B receptors mediate contraction of smooth muscle in human small intestine
28. 4 receptor in the secretory response of human small intestine to 5-HT
29. A review of central 5-HT receptors and their function
30. 5-Hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: Clinical implications
31. 3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: A segmental perfusion study
32. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism
33. Effect of a 5HT-3 antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome
34. 3 antagonist (GR38032F) on small intestinal transit and release of gastrointestinal peptides
35. GR 38032F (Ondanestron), a selective 5-HT 3 receptor antagonist, slows colonic transit in healthy man
36. 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: A pilot study
37. 3 antagonist, in patients with irritable bowel syndrome
38. Cilansetron shows efficacy in male and female non-constipated patients with irritable bowel syndrome in a United States study
39. Review article: Tegaserod
40. Tropisetron. A review of the clinical experience
41. Alosetron
42. 3 receptor antagonist alosetron inhibits the colorectal distension induced depressor response and spinal c-fos expression in the anaesthetised rat
43. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
44. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome
45. 3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers
46. Anxiolytic potential of 5-HT3 receptor antagonists
47. 3 receptor antagonist
48. Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial
49. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients
50. A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia
51. Gender differences in regional brain response to visceral pressure in IBS patients
52. Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomized, controlled trials
53. Role of loperamide and placebo in management of irritable bowel syndrome (IBS)
54. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome
55. Ischemic colitis during treatment with alosetron
56. Lotronex and the FDA: A fatal erosion of integrity
57. Nutrient tasting and signalling mechanisms in the gut II. The intestine as a sensory organ: Neural, endocrine, and immune response
58. 5-HT 3 and 5-HT 4 receptor-mediated facilitation of the emptying phase of the peristaltic reflex in the marmoset isolated ileum
59. 5-HT 4 receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle
60. 5-Hydroxytryptamine 4 receptor agonists initiate the peristaltic reflex in human, rat and guinea pig intestines
61. Characterization of the 5-hydroxytryptamine receptor type involved in inhibition of spontaneous activity of human isolated colonic circular muscle
62. Inhibition of motility induced by the activation of 5-HT1-like and 5-HT4-like receptors in isolated human colon smooth muscle
63. Human colonic mucosa possesses a mixed population of 5-hydroxytrypamine receptors
64. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation
65. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease
66. Multiple-dose phamacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF919)
67. Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration
68. 4 receptor agonist, in a model of slow colonic transit
69. Dose-dependent modulation of rectal afferent sensitivity by a 5HT 4 receptor agonist
70. Tegaserod
71. Tegaserod accelerates corocecal transit in patients with constipation-predominant irritable bowel syndrome
72. Tegaserod, a 5HT 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation
73. Tegaserod provides relief of symptoms in female patients with irritable bowel syndrome (IBS) suffering from abdominal pain and discomfort, bloating and constipation
74. Effect of a novel prokinetic drug, RO93877, on gastrointestinal transit in healthy volunteers
75. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers
76. Colonic mass movements in idiopathic chronic constipation
77. Prucalopride accelerate gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder
78. Prucalopride (PRU) improves bowel movement (BM) frequency and symptoms (Sx) in patients (PTS) with chronic constipation (CC): Results of two double-blind placebo-controlled trials
79. Effects of a serotonin 5HT 4 receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans
80. MKC-733, a 5HT3 receptor agonist, stimulates small bowel transit and relaxes the gastric fundus in man
81. Functional evidence for a 5HT2B receptor mediating contraction of longitudinal muscle in human small intestine
82. Evidence for 5-HT7 receptors mediating relaxation of human colonic circular smooth muscle
83. Management of irritable bowel syndrome: Novel approaches to the pharmacology of gut motility
84. The CCKa receptor-antagonist dexloxiglumide in the treatment of IBS
85. Misoprostol in the treatment of chronic refactory constipation: Results of a long-term open label trial
86. Towards identifying optimal doses for alpha 2 adrenergic modulation of colonic and rectal motor and sensory function
87. Double-blind study of an alpha 2 agonist in the treatment of the irritable bowel syndrome
88. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
89. Role of tachykinin NK2 receptors in normal and altered rectal sensitivity in rats
90. Peripheral actions of tachykinins
91. Possible site of action of TAK-637, a tachykinin NK(1) receptor antagonist, on the micturition reflex in guinea pigs
92. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone
93. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome: A multicenter dose-response study
94. Treatment of functional gastrointestinal disorders with anti-depressant medications: A meta-analysis
95. Influence of antidepressants on whole gut and orocaecal transit times in healthy irriatble bowel syndrome
96. Some of the challenges in drug development for irritable bowel syndrome